FLEBOGAMMA 10% 100 MG
IMMUNOGLOBULIN (HUMAN) : 100 MG · DIN 02467526 · INSTITUTO GRIFOLS S.A.
Health Canada status: APPROVED
What is FLEBOGAMMA 10%?
FLEBOGAMMA 10% 100 MG contains IMMUNOGLOBULIN (HUMAN) : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02467526, held by INSTITUTO GRIFOLS S.A., supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 17-Aug-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02467526 |
|---|---|
| Brand name | FLEBOGAMMA 10% |
| Generic / active ingredient | IMMUNOGLOBULIN (HUMAN) : 100 MG |
| Manufacturer | INSTITUTO GRIFOLS S.A. |
| Strength | 100 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | J06BA02 IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASC. ADM. |
| AHFS class | 08:12.06.16 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 17-Aug-2017 |
| Original market date | 2018-05-14 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code J06BA02 IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASC. ADM.. 5 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| GAMMAGARD LIQUID | 10 % | SOLUTION | TAKEDA CANADA INC | MARKETED | DIN 02279444 |
| GAMMAGARD S/D | 5 G | SOLUTION ; POWDER FOR SOLUTION ; KIT | TAKEDA CANADA INC | MARKETED | DIN 02231470 |
| GAMUNEX | 10 G / 100 ML | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | DIN 02247724 |
| IGIVNEX | 10 G / 100 ML | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | DIN 02277921 |
| PRIVIGEN | 10 % | SOLUTION | CSL BEHRING CANADA INC | MARKETED | DIN 02304619 |
| FLEBOGAMMA 5% | 50 MG | SOLUTION | INSTITUTO GRIFOLS S.A. | APPROVED | DIN 02467488 |
| GAMIMUNE N 10% (IV) | 100 MG | SOLUTION | TALECRIS BIOTHERAPEUTICS INC | CANCELLED POST MARKET | DIN 02229695 |
| GAMIMUNE N 5% (IV) | 50 MG | SOLUTION | TALECRIS BIOTHERAPEUTICS INC | CANCELLED POST MARKET | DIN 02178842 |
| GAMIMUNE N INJ 5% (IV) | 50 MG | LIQUID | CUTTER MED & BIOL, DIVISION OF MILES CANADA LTD. | CANCELLED POST MARKET | DIN 00559261 |
| GAMMAGARD S/D | 10 G | SOLUTION ; KIT ; POWDER FOR SOLUTION | TAKEDA CANADA INC | DORMANT | DIN 02231471 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.